• 154,692+ Medical Conferences
  • 285 Specialties
  • 11,299 Organizers
  • 156,527 Speakers
  • 159 Countries
  • 4,789 Cities
CME Conference Registrations Sold


Lifestyle Intervention Only Offers Modest Benefit in Type 2 Diabetes

Lifestyle Intervention Only Offers Modest Benefit in Type 2 Diabetes

Wed, Aug 16, 2017

TUESDAY, Aug. 15, 2017 (HealthDay News) -- For adults with type 2 diabetes diagnosed for less than 10 years, a lifestyle intervention resulted in a beneficial change in glycemic control that did not reach the criterion for equivalence, according to a study published in the Aug. 15 issue of the Journal of the American Medical Association.

Mette Yun Johansen, from the University of Copenhagen in Denmark, and colleagues conducted a randomized study involving 98 adults with non-insulin-dependent type 2 diabetes who had been diagnosed for less than 10 years. Participants were randomized to the lifestyle group or standard care (64 and 34, respectively). All participants received standard care with individual counseling and target-driven medical therapy; the lifestyle intervention group also included weekly aerobic and resistance training, as well as dietary plans, aiming for a body mass index of 25 kg/m² or less.

Ninety-three of the participants completed the trial. The researchers found that the mean hemoglobin A1c level changed from 6.65 to 6.34 percent in the lifestyle group and from 6.74 to 6.66 percent in the standard-care group from baseline to 12-month follow-up (mean between-group difference in change, −0.26 percent; 95 percent confidence interval, −0.52 to −0.01 percent), which did not meet the criteria for equivalence (P = 0.15). Overall, 73.5 percent of participants in the lifestyle group and 26.4 percent in the standard-care group had a reduction in glucose-lowering medications.

"Further research is needed to assess superiority, as well as generalizability and durability of findings," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; the Contour Next glucose monitors were provided by Bayer.

Abstract/Full Text (subscription or payment may be required)